Therapeutic Drug Monitoring Market Report 2026

Therapeutic Drug Monitoring Market Overview

• Therapeutic Drug Monitoring market size has reached to $2.41 billion in 2025 • Expected to grow to $4.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.2% • Growth Driver: Increasing Consumption Of Drugs Is Anticipated To Fuel The Therapeutic Drug Monitoring Market • Market Trend: Advancements In Anti-Idiotypic Antibody Technology Transforming Therapeutic Drug Monitoring • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Therapeutic Drug Monitoring Market?

Therapeutic drug monitoring (TDM) is a clinical procedure in which a patient's bloodstream is continuously monitored for the concentration of a specific medicine to ensure that their dose regimens are functioning effectively. It is used to monitor pharmaceuticals for which target concentrations are difficult to monitor, medications with significant pharmacokinetic variability, medications with established therapeutic and negative side effects, and medications with narrow therapeutic ranges. The main product types of therapeutic drug monitoring include consumables, equipment, immunoassay analyzers, chromatography, and detectors. Therapeutic drug monitoring consumables are reagents and supplies that are used in conjunction with TDM assays. The different technologies used include immunoassays, chemiluminescence immunoassays, colorimetric immunoassays, fluorescence immunoassays, radioimmunoassay, other immunoassays, chromatography-ms, lc-ms and gc-mc that consists of different classes of drugs including antiseptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive drugs and other drugs for use in various end-users such as hospital laboratories, commercial and private laboratories, and other end-users.

What Is The Therapeutic Drug Monitoring Market Growth Forecast?

The therapeutic drug monitoring market size is expected to see rapid growth in the next few years. It will grow to $4.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to growing demand for precision medicine, expansion of automated diagnostic laboratories, increasing focus on patient-specific dosing, advancements in mass spectrometry technologies, rising adoption of real-time therapeutic monitoring. Major trends in the forecast period include increasing adoption of lc-ms based monitoring techniques, rising use of personalized medicine approaches, growing integration of automated laboratory systems, expansion of real-time drug level analysis, enhanced focus on precision dosing.

Global Therapeutic Drug Monitoring Market Segmentation

1) By Product: Consumables, Equipment, Immunoassay Analyzers, Chromatography And Detectors 2) By Class Of Drug: Antiepileptic Drugs, Antibiotic Drugs, Immunosuppressant Drugs, Antiarrhythmic Drugs, Psychoactive Drugs, Other Drugs 3) By End-user: Hospital Laboratories, Commercial and Private Laboratories, Other End Users Subsegments: 1) By Consumables: Reagents, Test Kits, Sample Collection Containers, Calibration Standards 2) By Equipment: Analyzers, Incubators, Centrifuges 3) By Immunoassay Analyzers: ELISA Analyzers, Chemiluminescent Immunoassay Analyzers, Radioimmunoassay Analyzers 4) By Chromatography And Detectors: High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Mass Spectrometry (MS)

What Is The Driver Of The Therapeutic Drug Monitoring Market?

The increasing consumption of drugs is expected to propel the growth of the therapeutic drug monitoring market going forward. Drugs are substances used for medical purposes to diagnose, treat, or prevent diseases in humans or animals. Therapeutic drug monitoring is employed to optimize drug dosage regimens by measuring and adjusting drug concentrations in the bloodstream, ensuring efficacy while minimizing side effects. For instance, in January 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, across the period from April 2022 to March 2023, a total of 12,418 young people under 18 engaged with alcohol and drug services, representing a 10% rise from the previous year’s 11,326 cases. Therefore, the increasing consumption of drugs is driving the therapeutic drug monitoring industry.

Key Players In The Global Therapeutic Drug Monitoring Market

Major companies operating in the therapeutic drug monitoring market are Abbott Laboratories Inc., F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Sekisui Medical Co., Buehlmann Laboratories AG, Danaher Corporation, Bio-Rad Laboratories Inc., bioMérieux SA, Randox Laboratories Limited, Chromsystems Instruments & Chemicals GmbH, Grifols SA, Merck KGaA, BioChem Pharmaceuticals, Beckman Coulter Inc., DiaSorin S.p.A., Hologic Inc., Immunodiagnostic Systems Holdings plc, Kronus Inc., QuidelOrtho Corporation, Sysmex Corporation, TDM Solutions Inc., Theradiag, Tosoh Bioscience LLC, Trinity Biotech plc, Associated Regional and University Pathologists Inc., Mayo Clinic Laboratories, Quest Diagnostics

Global Therapeutic Drug Monitoring Market Trends and Insights

Major companies in the therapeutic drug monitoring market are focusing on the development of anti-idiotypic antibody technology to enhance the sensitivity and specificity of assays for accurately measuring biologic drug levels and assessing patient immune responses. Anti-idiotypic antibody technology is helpful in therapeutic drug monitoring by enabling precise detection and measurement of biologic drug levels, ensuring accurate dosing, and tracking of patient immune responses. For instance, in June 2024, Bio-Rad Laboratories, a US-based biotechnology company, launched new anti-idiotypic and anti-monomethyl auristatin E (MMAE) antibodies for bioanalytical assays, improving pharmacokinetic (PK) and antidrug-antibody (ADA) monitoring. These innovative antibodies enhance the reliability of assays for antibody-drug conjugates (ADCs) and are crucial for the therapeutic drug monitoring market, enabling precise assessments of drug levels and immune responses for optimal patient dosing.

What Are Latest Mergers And Acquisitions In The Therapeutic Drug Monitoring Market?

In February 2023, Sentinel Diagnostics, an Italian in vitro diagnostic company, acquired Eureka S.r.l. for an undisclosed amount. This acquisition allows Sentinel Diagnostics to achieve its goal of becoming a significant producer and developer of IVD tests. Sentinel Diagnostics will be able to provide clinical laboratories with a larger selection of assays due to its expanded capabilities, ranging from high-throughput core lab tests to the most cutting-edge, specialized second-level assays. EUREKA S.r.l. is an Italian IVD chromatographic company that provides ready-to-use diagnostic kits for HPLC, GC, GC-MS, and LC-MS/MS applications for special clinical chemistry, therapeutic drug monitoring, occupational toxicology, and forensic toxicology.

Regional Outlook

North America was the largest region in the therapeutic drug monitoring market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global therapeutic drug monitoring market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Therapeutic Drug Monitoring Market?

The therapeutic drug monitoring market includes revenues earned by entities by providing drug monitoring, urine drug testing, drug efficacy testing, and drug toxicology. The market value includes the value of related goods sold by the service provider or included within the service offering. The therapeutic drug monitoring market also includes sales of Immunoassay kits, Mass spectrometry instruments, and Chromatography systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.